Free Trial

Helix BioPharma (HBP) Competitors

Helix BioPharma logo
C$0.80 0.00 (0.00%)
As of 04/1/2025 09:30 AM Eastern

HBP vs. BCT, IPA, SCYB, COM, NVH, IGX, MDNA, TH, ONC, and PDP

Should you be buying Helix BioPharma stock or one of its competitors? The main competitors of Helix BioPharma include BriaCell Therapeutics (BCT), ImmunoPrecise Antibodies (IPA), Scythian Biosciences (SCYB), 138267 (COM.TO) (COM), Novoheart (NVH), IntelGenx Technologies (IGX), Medicenna Therapeutics (MDNA), Theratechnologies (TH), Oncolytics Biotech (ONC), and Pediapharm (PDP). These companies are all part of the "biotechnology" industry.

Helix BioPharma vs.

Helix BioPharma (TSE:HBP) and BriaCell Therapeutics (CVE:BCT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, community ranking, risk and valuation.

Helix BioPharma's return on equity of 1,803.57% beat BriaCell Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Helix BioPharmaN/A 1,803.57% -279.98%
BriaCell Therapeutics N/A N/A N/A

In the previous week, Helix BioPharma's average media sentiment score of 0.00 equaled BriaCell Therapeutics'average media sentiment score.

Company Overall Sentiment
Helix BioPharma Neutral
BriaCell Therapeutics Neutral

BriaCell Therapeutics is trading at a lower price-to-earnings ratio than Helix BioPharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Helix BioPharmaN/AN/A-C$50.55M-C$0.95-0.84
BriaCell TherapeuticsN/AN/AN/A-C$0.38-28.19

Helix BioPharma received 26 more outperform votes than BriaCell Therapeutics when rated by MarketBeat users. However, 68.97% of users gave BriaCell Therapeutics an outperform vote while only 63.46% of users gave Helix BioPharma an outperform vote.

CompanyUnderperformOutperform
Helix BioPharmaOutperform Votes
66
63.46%
Underperform Votes
38
36.54%
BriaCell TherapeuticsOutperform Votes
40
68.97%
Underperform Votes
18
31.03%

Summary

Helix BioPharma and BriaCell Therapeutics tied by winning 3 of the 6 factors compared between the two stocks.

Remove Ads
Get Helix BioPharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for HBP and its competitors with MarketBeat's FREE daily newsletter.

HBP vs. The Competition

MetricHelix BioPharmaBiotechnology IndustryMedical SectorTSE Exchange
Market CapC$42.42MC$114.66MC$5.55BC$5.70B
Dividend Yield1.50%3.69%5.35%6.44%
P/E Ratio-0.843.1223.4231.87
Price / SalesN/A4,029.45363.77579.73
Price / Cash11.3213.0138.1683.21
Price / Book-5.7535.386.613.56
Net Income-C$50.55M-C$87.82MC$3.20BC$299.69M
7 Day PerformanceN/A-4.41%-5.01%-1.05%
1 Month PerformanceN/A57.56%-1.58%-0.16%
1 Year Performance344.44%85.27%8.59%14.01%

Helix BioPharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HBP
Helix BioPharma
N/AC$0.80
flat
N/A+344.4%C$42.42MN/A-0.849
BCT
BriaCell Therapeutics
N/AC$10.60
-3.8%
C$15.00
+41.5%
+0.0%C$168.68MN/A-28.195
IPA
ImmunoPrecise Antibodies
N/AC$6.50
+0.8%
N/A+0.0%C$162.08MC$19.47M-7.3080Gap Down
SCYB
Scythian Biosciences
N/AC$3.49
-5.9%
N/A+0.0%C$102.38MN/A0.00N/AHigh Trading Volume
COM
138267 (COM.TO)
N/AN/AN/AN/AC$102.19MN/A0.00N/A
NVH
Novoheart
N/AC$0.53
+1.9%
N/A+0.0%C$99.98MC$423,500.00-13.95N/A
IGX
IntelGenx Technologies
N/AC$0.58
+1.8%
N/A+0.0%C$87.32MC$1.75M-7.442,050Gap Up
MDNA
Medicenna Therapeutics
N/AC$0.99
flat
N/A-46.4%C$74.07MC$4,868.39-2.7320News Coverage
TH
Theratechnologies
N/AC$2.21
-2.2%
N/A-1.4%C$70.51MC$52.22M-25.02103
ONC
Oncolytics Biotech
0.2333 of 5 stars
C$0.91
+2.2%
C$3.50
+284.6%
-46.2%C$70.14MN/A-2.5429Negative News
Gap Down
PDP
Pediapharm
N/AC$0.30
+1.7%
N/A+0.0%C$66.36MC$11.16M-4.11N/A
Remove Ads

Related Companies and Tools


This page (TSE:HBP) was last updated on 4/2/2025 by MarketBeat.com Staff
From Our Partners